P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer to Strengthen Clinical Leadership
P3 Health Partners Inc., a patient-centered and physician-led population health management company, has announced the appointment of Dr. Michael Millie as its new Chief Clinical Officer, effective October 12, 2026. The appointment represents an important leadership development for the company as it continues to focus on physician-led healthcare delivery, population health management, and value-based care programs.
P3 Health Partners, which trades on the Nasdaq under the ticker symbol PIII, works to support healthcare providers and improve how care is coordinated and delivered to patients. Through its population health management approach, the company focuses on aligning clinical services, physician engagement, and healthcare delivery strategies to address the needs of patients and the broader healthcare system.
Dr. Millie joins P3 with experience in physician leadership, clinical operations, and value-based care. Most recently, he served as a Chief Medical Officer, where he oversaw clinical programs and initiatives designed to support value-based healthcare delivery. His background as a surgeon, combined with his experience in healthcare leadership and business administration, provides a foundation for his new responsibilities at P3.
The appointment comes at a time when healthcare organizations are increasingly focused on improving care coordination, managing medical costs, supporting physicians, and delivering services that emphasize patient outcomes. Clinical leadership plays an important role in these efforts by connecting medical expertise with organizational strategy and operational decision-making.
In addition to announcing Dr. Millie’s appointment, P3 Health Partners disclosed that its Compensation and Nominating Committee approved a non-qualified stock option award as a material inducement to his employment. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4), which permits certain equity awards to be issued to new employees outside a shareholder-approved equity compensation plan, subject to applicable requirements.
Dr. Michael Millie Brings Physician Leadership and Clinical Experience
Dr. Michael Millie brings a combination of clinical training and executive experience to his new role as Chief Clinical Officer at P3 Health Partners. His professional background includes surgical training and leadership responsibilities involving clinical and value-based care programs.
He earned his Doctor of Medicine degree from the University of Nebraska Medical Center and holds a Master of Business Administration degree from the University of Washington. These qualifications combine medical education with formal business training, providing experience relevant to healthcare organizations that must balance clinical priorities with operational and financial considerations.
His most recent position was as a Chief Medical Officer, where he oversaw clinical and value-based care programs. Such responsibilities generally involve coordinating clinical priorities, supporting medical professionals, and helping healthcare organizations implement care delivery strategies aligned with patient needs and organizational objectives.
As Chief Clinical Officer, Dr. Millie will join P3’s leadership team with experience spanning clinical practice and executive management. His surgical background provides a foundation in direct patient care, while his leadership experience offers an understanding of the organizational structures and processes required to manage clinical programs.
Healthcare organizations increasingly require leaders who can understand both the practical realities of medical care and the broader operational challenges involved in delivering services across patient populations.
Clinical leaders can contribute to the development of care models, support physician engagement, and help organizations evaluate how clinical practices align with quality objectives and patient needs. Their responsibilities may also involve working with other executives to establish priorities, assess performance, and identify opportunities to improve care delivery.
P3’s announcement identifies Dr. Millie’s experience overseeing clinical and value-based care programs as a central part of his professional background.
Population Health Management Remains a Key Healthcare Priority
Population health management focuses on understanding and addressing the healthcare needs of defined groups of patients. Rather than concentrating exclusively on individual medical encounters, this approach considers how preventive services, chronic disease management, care coordination, and ongoing patient engagement can contribute to better health outcomes.
For healthcare organizations, population health management can involve identifying patients who may benefit from additional support, coordinating services among different providers, and monitoring clinical needs over time.
These activities are particularly relevant for patients managing chronic conditions or requiring care from multiple healthcare professionals. When services are poorly coordinated, patients may experience delays, duplicated tests, gaps in follow-up, or difficulty navigating the healthcare system.
Physician-led organizations can help address these challenges by involving clinicians in care planning and decisions about how healthcare services should be organized.
P3 Health Partners describes itself as a patient-centered and physician-led population health management company. Its operating approach places physicians and patient needs at the center of its healthcare strategy.
Clinical leadership is important within this model because population health programs depend on the ability to translate clinical knowledge into practical care processes. Leaders must understand the needs of physicians and patients while supporting the systems and workflows necessary to coordinate care.
The appointment of a Chief Clinical Officer can help establish clear clinical leadership and provide an executive-level focus on medical priorities.
Dr. Millie’s previous experience overseeing clinical programs may be relevant to these responsibilities, particularly in areas that require collaboration between physicians, clinical teams, and organizational leadership.
Value-Based Care and Clinical Leadership
Value-based care is an approach to healthcare delivery and payment that places greater emphasis on the quality, effectiveness, and outcomes of care rather than relying exclusively on the volume of services provided.
Depending on the specific program and contractual arrangement, value-based care models may incorporate measures related to preventive care, chronic disease management, patient outcomes, healthcare utilization, and total medical costs.
These arrangements can require healthcare organizations to coordinate care more closely, monitor performance, and identify opportunities to deliver appropriate services efficiently.
For physicians and clinical teams, participating in value-based care programs may involve adapting workflows, improving communication across care settings, and using clinical information to guide treatment decisions.
For healthcare organizations, the approach also requires operational planning, performance measurement, and collaboration between clinical and administrative teams.
Clinical executives play a role in bringing these elements together. They can help ensure that organizational initiatives remain connected to medical priorities and that operational decisions take account of patient care requirements.
Dr. Millie’s experience overseeing value-based care programs provides relevant background for his appointment at P3 Health Partners.
His medical education and executive experience may support collaboration across clinical and business functions as the company manages its population health activities.
However, the company announcement does not specify particular initiatives, performance targets, or changes to clinical programs that will follow his appointment. The immediate development is the addition of an experienced physician executive to P3’s leadership structure.
Appointment Effective October 12, 2026
P3 Health Partners confirmed that Dr. Millie’s appointment as Chief Clinical Officer became effective on October 12, 2026.
The appointment adds a physician executive with clinical training and experience in healthcare program oversight to the company’s senior leadership team.
Executive appointments can be significant for healthcare organizations because leaders help establish priorities, coordinate resources, and support the implementation of business and clinical strategies.
In population health management, clinical leadership is particularly relevant because organizational performance depends partly on how effectively medical professionals and operational teams work together.
A Chief Clinical Officer may help guide clinical strategy, support the development of care programs, and contribute to discussions about quality, care delivery, and physician engagement. The precise scope of Dr. Millie’s responsibilities will depend on P3’s internal structure and the duties assigned to him.
His appointment also brings together two areas of expertise: medicine and business administration. The combination can be useful in organizations operating within healthcare payment models that require attention to both patient outcomes and financial performance.
P3’s announcement does not outline a specific restructuring or a new strategic program associated with the appointment. Instead, it confirms Dr. Millie’s selection for the Chief Clinical Officer position and provides information about his qualifications.
P3 Health Partners Approves Equity Incentive Award
Alongside the leadership announcement, P3 Health Partners disclosed the approval of a non-qualified stock option award for Dr. Millie.
The company’s Compensation and Nominating Committee approved the award as a material inducement to his employment. The grant was made under Nasdaq Listing Rule 5635(c)(4), which addresses certain equity compensation awards issued to individuals entering employment with a company.
The rule provides a framework for qualifying inducement awards to be granted outside a shareholder-approved equity compensation plan, subject to applicable conditions and disclosure requirements.
According to P3, Dr. Millie was not previously an employee or director of the company before his appointment.
The stock option gives him the right to purchase 110,000 shares of P3 Health Partners’ Class A common stock, subject to the terms of the award.
The exercise price per share is equal to the closing price of the company’s Class A common stock on October 12, 2026, the grant date.
The option has a term of ten years. This term establishes the period during which the option may be exercised, subject to the award’s conditions and applicable rules.
The grant is intended to form part of the compensation arrangement associated with Dr. Millie’s employment.
Stock Option Vesting Schedule and Conditions
The stock option award is subject to a four-year vesting schedule, provided Dr. Millie continues to provide services to P3 Health Partners.
Under the disclosed terms, 25% of the underlying shares will vest and become exercisable on each of the first four anniversaries of the October 12, 2026, grant date.
The vesting schedule distributes the award over four years rather than making the entire option immediately exercisable.
The option covers 110,000 shares in total. Based on the stated 25% annual vesting schedule, 27,500 shares would vest at each anniversary, assuming the applicable continued-service conditions are satisfied and no other award terms alter the outcome.
The first scheduled vesting date would be October 12, 2027, followed by October 12, 2028, October 12, 2029, and October 12, 2030.
The final portion would therefore be scheduled to vest on the fourth anniversary of the grant date, subject to the award’s conditions.
Stock options differ from direct stock grants because they provide the right to purchase shares at a specified exercise price rather than automatically transferring the underlying shares to the recipient.
The financial value of an option depends on several factors, including the company’s share price relative to the exercise price, the remaining option term, and the applicable conditions governing exercise.
The award does not mean that Dr. Millie immediately receives 110,000 shares of common stock. Instead, it establishes an option to purchase the shares as the award vests and becomes exercisable under its terms.
Inducement Award Granted Outside the 2021 Incentive Award Plan
P3 confirmed that the option was granted as a stand-alone inducement award outside the P3 Health Partners Inc. 2021 Incentive Award Plan.
Although the award is outside that plan, the company stated that it is generally subject to the same terms and conditions that apply to awards granted under the plan.
This distinction is relevant because companies may use equity incentives to recruit executives and other employees while maintaining separate arrangements for awards that qualify as inducements to employment.
Nasdaq Listing Rule 5635(c)(4) permits certain employment-inducement awards without shareholder approval when the applicable conditions are met. Public disclosure of such awards is also required under the rule.
P3’s announcement provides the key information associated with the grant, including the number of underlying shares, exercise price determination, grant date, option term, and vesting schedule.
The disclosure offers investors information about the equity-based compensation associated with the executive appointment.
Strengthening Clinical Leadership at P3 Health Partners
Dr. Michael Millie’s appointment as Chief Clinical Officer marks a leadership development for P3 Health Partners as the company continues to operate in the population health management sector.
His background as a surgeon, his medical degree from the University of Nebraska Medical Center, his MBA from the University of Washington, and his experience overseeing clinical and value-based care programs provide the professional foundation described in the company’s announcement.
For organizations focused on physician-led healthcare delivery, clinical executives can help connect medical expertise with operational planning and organizational objectives.
Population health management requires coordination across multiple dimensions of care, including preventive services, ongoing patient support, physician engagement, and the management of clinical programs. Leadership experience in these areas can be relevant to organizations seeking to support coordinated care delivery.
The appointment also highlights the compensation arrangements accompanying the executive’s employment, including the 110,000-share non-qualified stock option with a ten-year term and a four-year vesting schedule.
While P3 has not announced specific operational changes resulting from Dr. Millie’s appointment, the addition of a Chief Clinical Officer establishes a senior leadership role for clinical oversight within the organization.
As healthcare providers and population health companies continue to navigate evolving care delivery and reimbursement models, experienced clinical leadership remains an important component of organizational management.
P3 Health Partners’ announcement brings together two key developments: the appointment of Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026, and the approval of an employment-inducement stock option award under the applicable Nasdaq requirements.
Source link: https://www.businesswire.com/
